Applications of Endomorphin-2 in Industrial Manufacturing

Endomorphin-2 is a precision-synthesized tetrapeptide with selective activity on μ-opioid receptors. Its high affinity, biological stability, and safety profile allow integration into advanced pharmaceuticals, biomedical research, analytical standards, and preclinical development. As a manufacturer, we support these downstream industries with consistent quality and documentation to meet regulatory and production needs.

1. Active Pharmaceutical Ingredient (API) Development for Analgesic Formulations

Pharmaceutical companies use Endomorphin-2 in the research and pilot-scale manufacture of novel analgesic drugs targeting pain management indications. Its selective mode of action and favorable pharmacokinetics permit developers to formulate products with reduced side-effect profiles when compared to traditional opioids. During preclinical and early clinical phases, Endomorphin-2 undergoes combination with excipients, stabilizers, and injectable carriers under strict GMP conditions, proceeding through analytical and bioassay validation. The endpoint is usually injectable or oral solid dosage forms for regulatory submission.

Industry compliance standards

• ICH Q7 (Good Manufacturing Practice for APIs)
• EU-GMP and US FDA 21 CFR Part 210/211
• Ph. Eur., USP, JP monograph listings for synthetic peptides (if applicable)
• ICH M3(R2) for nonclinical safety studies

Typical usage ratio

• 0.1 mg to 10 mg per dose; batch formulation ranges from 0.01% to 0.5% w/w, adjusted according to dosage form, release profile, and toxicology data

Downstream process integration

• Entry at API compounding stage, post-solid-phase peptide synthesis and purification
• Blending with excipients followed by granulation or lyophilization
• Filling and packaging in sterile or solid dosage format

Final product types

• Oral tablets and capsules for pain management
• Injectable ampoules and pre-filled syringes
• Extended-release transdermal systems (patches)

2. Reference Standard Supply for Biomedical Assays

Research institutions and CROs require high-purity Endomorphin-2 as a reference standard for immunoassays, pharmacological receptor binding studies, and cell-based models. Accurate quantification and calibration demand tightly specified peptide lots. Peptide purity, identity, and content verification via HPLC and mass spectrometry occur before aliquoting for downstream assay calibration, ensuring reproducibility and traceability as required by GLP guidelines.

Industry compliance standards

• OECD Principles of Good Laboratory Practice
• ISO/IEC 17025 for calibration laboratories
• FDA GLP regulation 21 CFR Part 58
• Sigma-Aldrich and NIST traceability guidelines for reference materials

Typical usage ratio

• 1 μg – 100 μg per calibration; preparation of 0.01% – 0.05% stock solutions in assay buffers

Downstream process integration

• Dissolution and dilution for HPLC, LC-MS/MS, or immunoassay calibration standards
• Aliquoting into validated microvials under inert conditions
• Storage in controlled temperature facilities to maintain stability

Final product types

• Pharmacological assay kits
• Reference standards for academic and biotech laboratory use
• Analytical controls for CRO-operated high-throughput screening

3. Preclinical In Vivo Model Testing

Drug discovery companies, hospitals, and academic labs utilize Endomorphin-2 for in vivo pharmacodynamics studies in animal models exploring nociception, opioid tolerance, and receptor selectivity. The peptide’s stability and solubility allow precise dosing in rodent or non-primate models, with administration via intrathecal, intravenous, or subcutaneous routes. Dosing solution preparation and quality control are critical before animal testing, adhering to animal welfare regulations and project protocol standards.

Industry compliance standards

• AAALAC International accreditation for animal care
• EU Directive 2010/63/EU on the protection of animals used for scientific purposes
• US National Research Council Guide for the Care and Use of Laboratory Animals
• Institutional Animal Care and Use Committee (IACUC) protocols

Typical usage ratio

• 1 μg/kg to 5 mg/kg body weight; adjusted per animal weight, administration route, and experimental design

Downstream process integration

• Peptide reconstitution in physiological saline or DMSO solution
• Sterile filtration and aliquoting per cage or animal group schedule
• Documentation of dosage preparation and administration records

Final product types

• Rodent pharmacology study kits
• Testing batches for early-stage IND enabling studies
• Validated peptide lots for GLP or non-GLP animal trials

4. Custom Peptide Synthesis for Clinical Trial Materials

Contract development and manufacturing organizations (CDMOs) and large pharma require GMP-grade custom synthesized Endomorphin-2 for clinical trial supply. Synthesis processes involve resin selection, cycle-by-cycle amino acid coupling, cleavage, purification, and lyophilization. Each lot receives full documentation, with batch records, analytical certificate, and stability data to support clinical batch release. This enables controlled substance trial batches, conducted under explicit regulatory hold or expanded access programs.

Industry compliance standards

• FDA 21 CFR Part 312 (Investigational New Drug applications)
• EU-GMP Annex 13: Manufacture of Investigational Medicinal Products
• ICH Q9 (Quality Risk Management)
• ICH Q1A(R2) for stability testing of new drug substances

Typical usage ratio

• 10 mg to 500 mg per clinical batch; formulation strength set by protocol, placebo matching, or comparator group requirements

Downstream process integration

• Controlled GMP synthesis suite or small-scale reactor system
• In-process peptide purification, lyophilization, and sterile filtration
• Batch record compilation and quality release for clinical site shipment

Final product types

• Clinical trial vials for Phase I-II pain management studies
• GMP peptide reference standards for trial batch confirmation
• Comparator arms for double-blind opioid efficacy trials